- Home
- ACIU vs JGH Comparison
ACIU vs JGH Comparison
Compare ACIU & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- JGH
- Stock Information
- Founded
- ACIU 2003
- JGH 2014
- Country
- ACIU Switzerland
- JGH United States
- Employees
- ACIU N/A
- JGH N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- JGH Investment Managers
- Sector
- ACIU Health Care
- JGH Finance
- Exchange
- ACIU Nasdaq
- JGH Nasdaq
- Market Cap
- ACIU 332.4M
- JGH 308.3M
- IPO Year
- ACIU 2016
- JGH N/A
- Fundamental
- Price
- ACIU $2.68
- JGH $12.72
- Analyst Decision
- ACIU Strong Buy
- JGH
- Analyst Count
- ACIU 2
- JGH 0
- Target Price
- ACIU $12.00
- JGH N/A
- AVG Volume (30 Days)
- ACIU 134.5K
- JGH 73.9K
- Earning Date
- ACIU 11-05-2024
- JGH 01-01-0001
- Dividend Yield
- ACIU N/A
- JGH 9.85%
- EPS Growth
- ACIU N/A
- JGH N/A
- EPS
- ACIU N/A
- JGH N/A
- Revenue
- ACIU $48,505,404.00
- JGH N/A
- Revenue This Year
- ACIU $85.33
- JGH N/A
- Revenue Next Year
- ACIU $80.69
- JGH N/A
- P/E Ratio
- ACIU N/A
- JGH N/A
- Revenue Growth
- ACIU 4097200.00
- JGH N/A
- 52 Week Low
- ACIU $2.25
- JGH $10.36
- 52 Week High
- ACIU $5.14
- JGH $12.85
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- JGH 27.34
- Support Level
- ACIU $2.62
- JGH $13.14
- Resistance Level
- ACIU $3.02
- JGH $13.38
- Average True Range (ATR)
- ACIU 0.13
- JGH 0.11
- MACD
- ACIU -0.05
- JGH -0.07
- Stochastic Oscillator
- ACIU 9.52
- JGH 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.